Last reviewed · How we verify
Fluarix/Influsplit SSW 2012-2013
Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.
Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children ≥6 months of age (2012-2013 season).
At a glance
| Generic name | Fluarix/Influsplit SSW 2012-2013 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus antigens from three seasonal strains (trivalent formulation for 2012-2013 season). Upon intramuscular injection, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory immune cells that recognize and neutralize circulating influenza viruses.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age (2012-2013 season)
Common side effects
- Injection site soreness/pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old (PHASE4)
- A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluarix/Influsplit SSW 2012-2013 CI brief — competitive landscape report
- Fluarix/Influsplit SSW 2012-2013 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI